GreenLight Biosciences Holdings (GRNA) has a consensus analyst rating of Buy, based on 2 analysts covering the stock. Of those, 1 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for GRNA is $11.00, representing a +3,572.8% upside from the current price of $0.2995. Price targets range from a low of $4.00 to a high of $18.00.
